Publications 2024

Foote JB, Mattox TE, Keeton AB, Chen X, Smith FT, Berry K, Holmes TW, Wang J, Huang CH, Ward A, Mitra AK, Ramirez-Alcantara V, Hardy C, Fleten KG, Flatmark K, Yoon KJ, Sarvesh S, Nagaraju GP, Bandi DSR, Maxuitenko YY, Valiyaveettil J, Carstens JL, Buchsbaum DJ, Yang J, Zhou G et al. (2024)
A Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth and Induces Antitumor Immunity in Gastrointestinal Cancer
Cancer Res (in press)
DOI 10.1158/0008-5472.CAN-24-0323, PubMed 39700396

Publications 2023

Hyldbakk A, Fleten KG, Snipstad S, Åslund AKO, Davies CL, Flatmark K, Mørch Y (2023)
Intraperitoneal administration of cabazitaxel-loaded nanoparticles in peritoneal metastasis models
Nanomedicine, 48, 102656
DOI 10.1016/j.nano.2023.102656, PubMed 36646195

Ito I, Yousef AM, Dickson PN, Naini ZA, White MG, Fleten KG, Flatmark K, Fournier KF, Fowlkes NW, Shen JP (2023)
Antitumor activity of intraperitoneal paclitaxel in orthotopic patient-derived xenograft models of mucinous appendiceal adenocarcinoma
bioRxiv
DOI 10.1101/2023.02.01.526672, PubMed 36993681

Ito I, Yousef AMG, Chowdhury S, Dickson PN, Naini ZA, White MG, Fleten KG, Flatmark K, Fournier KF, Fowlkes NW, Shen JP (2023)
Intraperitoneal Paclitaxel Is a Safe and Effective Therapeutic Strategy for Treating Mucinous Appendiceal Adenocarcinoma
Cancer Res, 83 (19), 3184-3191
DOI 10.1158/0008-5472.CAN-23-0013, PubMed 37433032

Publications 2022

Fleten KG, Hyldbakk A, Einen C, Benjakul S, Strand BL, Davies CL, Mørch Ý, Flatmark K (2022)
Alginate Microsphere Encapsulation of Drug-Loaded Nanoparticles: A Novel Strategy for Intraperitoneal Drug Delivery
Mar Drugs, 20 (12)
DOI 10.3390/md20120744, PubMed 36547891

Fusser M, Øverbye A, Pandya AD, Mørch Ý, Borgos SE, Kildal W, Snipstad S, Sulheim E, Fleten KG, Askautrud HA, Engebraaten O, Flatmark K, Iversen TG, Sandvig K, Skotland T, Mælandsmo GM (2022)
Corrigendum to "Cabazitaxel-loaded Poly(2-ethylbutyl cyanoacrylate) nanoparticles improve treatment efficacy in a patient derived breast cancer xenograft", [Journal of Control Release, 293 (2019) 183-192]
J Control Release, 349, 1
DOI 10.1016/j.jconrel.2022.06.040, PubMed 35792388

Nyakas M, Fleten KG, Haugen MH, Engedal N, Sveen C, Farstad IN, Flørenes VA, Prasmickaite L, Mælandsmo GM, Seip K (2022)
AXL inhibition improves BRAF-targeted treatment in melanoma
Sci Rep, 12 (1), 5076
DOI 10.1038/s41598-022-09078-z, PubMed 35332208

Publications 2021

Andersson Y, Fleten KG, Abrahamsen TW, Reed W, Davidson B, Flatmark K (2021)
Anti-Angiogenic Treatment in Pseudomyxoma Peritonei-Still a Strong Preclinical Rationale
Cancers (Basel), 13 (11)
DOI 10.3390/cancers13112819, PubMed 34198773

Flatmark K, Torgunrud A, Fleten KG, Davidson B, Juul HV, Mensali N, Lund-Andersen C, Inderberg EM (2021)
Peptide vaccine targeting mutated GNAS: a potential novel treatment for pseudomyxoma peritonei
J Immunother Cancer, 9 (10)
DOI 10.1136/jitc-2021-003109, PubMed 34711663

Fleten KG, Eksteen JJ, Mauseth B, Camilio KA, Vasskog T, Sveinbjørnsson B, Rekdal Ø, Mælandsmo GM, Flatmark K (2021)
Oncolytic peptides DTT-205 and DTT-304 induce complete regression and protective immune response in experimental murine colorectal cancer
Sci Rep, 11 (1), 6731
DOI 10.1038/s41598-021-86239-6, PubMed 33762676

Lund-Andersen C, Torgunrud A, Fleten KG, Flatmark K (2021)
Omics analyses in peritoneal metastasis-utility in the management of peritoneal metastases from colorectal cancer and pseudomyxoma peritonei: a narrative review
J Gastrointest Oncol, 12 (Suppl 1), S191-S203
DOI 10.21037/jgo-20-136, PubMed 33968437

Publications 2020

Fleten KG, Lund-Andersen C, Waagene S, Abrahamsen TW, Mørch Y, Boye K, Torgunrud A, Flatmark K (2020)
Experimental Treatment of Mucinous Peritoneal Metastases Using Patient-Derived Xenograft Models
Transl Oncol, 13 (8), 100793
DOI 10.1016/j.tranon.2020.100793, PubMed 32447231

Publications 2018

Fusser M, Øverbye A, Pandya AD, Mørch Ý, Borgos SE, Kildal W, Snipstad S, Sulheim E, Fleten KG, Askautrud HA, Engebraaten O, Flatmark K, Iversen TG, Sandvig K, Skotland T, Mælandsmo GM (2018)
Cabazitaxel-loaded Poly(2-ethylbutyl cyanoacrylate) nanoparticles improve treatment efficacy in a patient derived breast cancer xenograft
J Control Release, 293, 183-192
DOI 10.1016/j.jconrel.2018.11.029, PubMed 30529259

Publications 2017

Andersson Y, Haavardtun SI, Davidson B, Dørum A, Fleten KG, Fodstad Ø, Flatmark K (2017)
MOC31PE immunotoxin - targeting peritoneal metastasis from epithelial ovarian cancer
Oncotarget, 8 (37), 61800-61809
DOI 10.18632/oncotarget.18694, PubMed 28977905

Publications 2016

Flatmark K, Saelen MG, Hole KH, Abrahamsen TW, Fleten KG, Hektoen HH, Redalen KR, Seierstad T, Dueland S, Ree AH (2016)
Individual tumor volume responses to short-course oxaliplatin-containing induction chemotherapy in locally advanced rectal cancer - Targeting the tumor for radiation sensitivity?
Radiother Oncol, 119 (3), 505-11
DOI 10.1016/j.radonc.2016.02.020, PubMed 26968754

Fleten KG, Bakke KM, Mælandsmo GM, Abildgaard A, Redalen KR, Flatmark K (2016)
Use of non-invasive imaging to monitor response to aflibercept treatment in murine models of colorectal cancer liver metastases
Clin Exp Metastasis, 34 (1), 51-62
DOI 10.1007/s10585-016-9829-3, PubMed 27812769

Fleten KG, Flørenes VA, Prasmickaite L, Hill O, Sykora J, Mælandsmo GM, Engesæter B (2016)
hvTRA, a novel TRAIL receptor agonist, induces apoptosis and sustained growth retardation in melanoma
Cell Death Discov, 2, 16081
DOI 10.1038/cddiscovery.2016.81, PubMed 28028438

Seip K, Fleten KG, Barkovskaya A, Nygaard V, Haugen MH, Engesæter BØ, Mælandsmo GM, Prasmickaite L (2016)
Fibroblast-induced switching to the mesenchymal-like phenotype and PI3K/mTOR signaling protects melanoma cells from BRAF inhibitors
Oncotarget, 7 (15), 19997-20015
DOI 10.18632/oncotarget.7671, PubMed 26918352

Publications 2015

Repetto-Llamazares AH, Larsen RH, Patzke S, Fleten KG, Didierlaurent D, Pichard A, Pouget JP, Dahle J (2015)
Targeted Cancer Therapy with a Novel Anti-CD37 Beta-Particle Emitting Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma
PLoS One, 10 (6), e0128816
DOI 10.1371/journal.pone.0128816, PubMed 26066655

Publications 2013

Flatmark K, Guldvik IJ, Svensson H, Fleten KG, Flørenes VA, Reed W, Giercksky KE, Fodstad Ø, Andersson Y (2013)
Immunotoxin targeting EpCAM effectively inhibits peritoneal tumor growth in experimental models of mucinous peritoneal surface malignancies
Int J Cancer, 133 (6), 1497-506
DOI 10.1002/ijc.28158, PubMed 23494569

Publications 2012

Saelen MG, Ree AH, Kristian A, Fleten KG, Furre T, Hektoen HH, Flatmark K (2012)
Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinoma
Radiat Oncol, 7, 165
DOI 10.1186/1748-717X-7-165, PubMed 23017053

Publications 2009

Størvold GL, Fleten KG, Olsen CG, Follestad T, Krokan HE, Schønberg SA (2009)
Docosahexaenoic acid activates some SREBP-2 targets independent of cholesterol and ER stress in SW620 colon cancer cells
Lipids, 44 (8), 673-83
DOI 10.1007/s11745-009-3324-4, PubMed 19582494